Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04341532

Enrollment

Registered

2020-04-10

Start date

2020-02-20

Completion date

2024-08-09

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

Pulmonary exacerbations (PEx) are key events that lead to a decline in health status among CF patients, with many never recovering to baseline health. With the advancement of new CFTR modulators and other therapies increasing the lifespan of those living with CF, it will become increasingly important to have better strategies to manage PEx in order to have better outcomes following treatment. PEx treatment decisions will need to take into consideration the increasing frequency of antimicrobial resistance bacteria and the need to treat multiple types of bacteria at once. The purpose of this study is to analyze sputum samples from CF subjects at the time of PEx in order to identify markers of antimicrobial resistant bacteria and see how those relate to treatment responses. CF patients will be recruited from patients followed by the Adult CF Program at National Jewish Health. Within 48 hours of admission to the hospital for treatment of a PEx, subjects will be enrolled and sputum will be collected. The sputum will be processed and analyzed for the presence of antimicrobial resistant bacteria. These results will be compared to clinical data, such as spirometry and frequency of hospitalizations.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CF patients 18 years or older who are hospitalized for IV treatment of an acute PEx * Chronically infected with Pseudomonas aeruginosa and/or Staphylococcus aureus * Can produce sputum * Can provide written consent * Willing to comply with study procedure

Exclusion criteria

* Subjects who are not colonized with Pseudomonas aeruginosa and/or Staphylococcus aureus * The presence of a condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the patient or the quality of the data

Design outcomes

Primary

Measure	Time frame	Description
Change in lung function	At initiation of IV antibiotic treatment and after one week of IV antibiotic treatment	Change in lung function as measured by FEV1, % predicted.
Targeted amplicon sequencing of sputum	Within 48 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation	Results from CF specific amplicon panel; this may include number and identity of bacterial species, presence or absence of AMR genes, frequencies of strain types, and AMR genes per total bacteria
Sputum microbiology	Within 48 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation	Traditional sputum microbiology results; this may include quantitative culture data for each pathogen, antimicrobial susceptibilities, and minimum inhibitory concentration (MIC)

Secondary

Measure	Time frame	Description
Changes in hospitalizations	12 months prior to enrollment to 12 months after enrollment	Changes in frequency/number of hospitalizations for treatment of CF pulmonary exacerbation
Antimicrobial regimens	Throughout course of hospitalization, on average 14 days	Type/total number of IV antibiotic doses delivered

Countries

United States

Outcome results